Skip to main content
Top
Published in: Updates in Surgery 3/2017

01-09-2017 | Review Article

Discrepancies between NCCN and ESMO guidelines in the management of anal cancer: a qualitative review

Authors: Natalie Johnson, Gianluca Pellino, Constantinos Simillis, Shengyang Qiu, Stella Nikolaou, Daniel L. Baird, Shahnawaz Rasheed, Paris P. Tekkis, Christos Kontovounisios

Published in: Updates in Surgery | Issue 3/2017

Login to get access

Abstract

There is an ever-growing need, with the ongoing developments in research and the progress towards patient centered care, to delineate standardized protocols of management of anal cancer. However, guidelines from different societies show some degree of disagreement. This is a systematic review of the literature to identify similarities and discrepancies between the guidelines for the management of anal cancer drafted by the European Society for Medical Oncology (ESMO) and by the National Comprehensive Cancer Network (NCCN). We found essentially similar management for investigation, diagnosis, chemotherapy regimens, and radiotherapy doses in both ESMO and NCCN recommendations in the management of anal cancer. There were few differences, which included the levels of evidence and grades of recommendations, the delineation of radiotherapy fields, and the treatment of the elderly and personalized medicine based on genetics. The follow-up regime is also marginally different in the first 2 years. Even if the observed differences may be justified by a different implementation of evidence-based medicine among different countries for particular management modalities of anal cancer, we identified the grey areas which need further study. In addition, these facets should be assessed more carefully when planning future guidelines.
Literature
1.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral
2.
go back to reference NCCN guidelines version 2.2015 anal carcinoma. NCCN.org NCCN guidelines version 2.2015 anal carcinoma. NCCN.org
3.
go back to reference Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D, ESMO, ESSO, ESTRO (2014) Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 111:330–339CrossRefPubMed Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, Arnold D, ESMO, ESSO, ESTRO (2014) Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Radiother Oncol 111:330–339CrossRefPubMed
4.
go back to reference Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE Jr, Sweet RL, Wenzel RP (1994) Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 18:421CrossRefPubMed Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE Jr, Sweet RL, Wenzel RP (1994) Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 18:421CrossRefPubMed
5.
go back to reference Poonacha TK, Go RS (2011) Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J Clin Oncol 29:186–191CrossRefPubMed Poonacha TK, Go RS (2011) Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J Clin Oncol 29:186–191CrossRefPubMed
6.
go back to reference Palefsky JM, Giuliano AR, Goldstone S et al (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:1576–1585CrossRefPubMed Palefsky JM, Giuliano AR, Goldstone S et al (2011) HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 365:1576–1585CrossRefPubMed
7.
go back to reference Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, Cats A (2014) Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 111:1726–1733CrossRefPubMedPubMedCentral Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, Cats A (2014) Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. Br J Cancer 111:1726–1733CrossRefPubMedPubMedCentral
8.
go back to reference Thind G, Johal B, Follwell M, Kennecke HF (2014) Chemoradiation with capecitabine and mitomycin-C for stage I–III anal squamous cell carcinoma. Radiat Oncol 9:124CrossRefPubMedPubMedCentral Thind G, Johal B, Follwell M, Kennecke HF (2014) Chemoradiation with capecitabine and mitomycin-C for stage I–III anal squamous cell carcinoma. Radiat Oncol 9:124CrossRefPubMedPubMedCentral
Metadata
Title
Discrepancies between NCCN and ESMO guidelines in the management of anal cancer: a qualitative review
Authors
Natalie Johnson
Gianluca Pellino
Constantinos Simillis
Shengyang Qiu
Stella Nikolaou
Daniel L. Baird
Shahnawaz Rasheed
Paris P. Tekkis
Christos Kontovounisios
Publication date
01-09-2017
Publisher
Springer Milan
Published in
Updates in Surgery / Issue 3/2017
Print ISSN: 2038-131X
Electronic ISSN: 2038-3312
DOI
https://doi.org/10.1007/s13304-017-0470-8

Other articles of this Issue 3/2017

Updates in Surgery 3/2017 Go to the issue